Evidence Level
Krill oil research centers on its unique phospholipid-bound omega-3 delivery system. Ulven et al. (2011) published the landmark bioavailability study in Lipids, demonstrating 68% greater EPA and DHA incorporation into red blood cell membranes compared to fish oil triglycerides at matched doses — a finding attributed to phospholipids being the native form of fatty acid transport in human cell membranes. Bunea et al. (2004) conducted a 12-week RCT showing krill oil reduced LDL cholesterol by 34%, triglycerides by 11.5%, and increased HDL by 43.5% in hyperlipidemic patients, outperforming fish oil on multiple endpoints. Sampalis et al. (2003) demonstrated significant PMS symptom relief with 2g krill oil daily across emotional and physical domains. Deutsch (2007) showed even low-dose krill oil (300mg/day) significantly reduced CRP and pain scores in patients with inflammatory conditions. A 2014 Cochrane-style review noted the overall evidence base for krill oil is smaller than fish oil's but consistently shows comparable or superior effects at lower doses, likely due to the phospholipid absorption advantage. The natural astaxanthin content (0.1-0.2mg per gram) provides oxidative stability superior to fish oil and may contribute independently to the anti-inflammatory benefits.